Assessing Health-related Quality of Life and Health Utilities in Patients with Chronic Hepatitis B-related Diseases in China: a Cross-sectional Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Sep 16

PMID 34526336

Citations 6

Authors

Meng Zhang

Yaoguang Li

Zihao Fan

Dongqi Shen

Xueying Huang

Qi Yu

Mei Liu

Feng Ren

Xiao Wang

Liping Dai

Peng Wang

Hua Ye

Jianxiang Shi

Xiaoang Yang

Shunxiang Zhang

Jianying Zhang

Affiliations

Soon will be listed here.

Abstract

Objectives: The health-related quality of life (HRQoL) and utilities of patients with chronic hepatitis B (CHB) virus infection, including compensated cirrhosis (CC), decompensated cirrhosis (DC) and different stages of hepatocellular carcinoma (HCC), have not been well described in China. This study aimed to evaluate HRQoL and utilities and provide parameters for the economic evaluation of CHB-related diseases.

Methods: We conducted a multicentre cross-sectional and study to measure the HRQoL of patients with CHB, CC, DC and HCC using the Chinese short form (SF) 36 health survey V.2. The utilities were extracted based on the SF-six dimension scoring model. Multivariable regression analyses identified the effects on HRQoL.

Results: A total of 1071 patients (639 with CHB, 125 with CC, 85 with DC and 222 with HCC) were invited to complete the questionnaire. Physical HRQoL was not impaired in the CHB stage, while mental HRQoL was significantly impaired. Physical composite summary scores have a more significant decrease than mental composite summary scores at the advanced stages (CC, DC and HCC). The utility scores of CHB only, CC, DC and HCC were 0.773, 0.750, 0.683 and 0.640, respectively. The utility scores in the early, middle and terminal stages of HCC were 0.656, 0.635 and 0.615, respectively.

Conclusion: Slowing the progress of CHB-related diseases and providing psychological support early are the key points to improving the quality of life with the diseases. The utility values estimated in this study can provide a vital instrument for cost-effectiveness studies on CHB-related diseases.

Citing Articles

Clinical effectiveness of entecavir versus tenofovir disoproxil fumarate tablets in chronic hepatitis B treatment.

Zhou Y, Shen Y, He J, Yang X Am J Transl Res. 2025; 16(12):7591-7599.

PMID: 39822557 PMC: 11733369. DOI: 10.62347/RKNH8649.

Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.

Liu R, Qiao J, Zhang L, Dou Z Medicine (Baltimore). 2024; 103(20):e37953.

PMID: 38758884 PMC: 11098221. DOI: 10.1097/MD.0000000000037953.

Effect of interferon therapy on quality of life in patients with chronic hepatitis B.

Zhang M, Wan M, Wang W, Lin S, Zhang X Sci Rep. 2024; 14(1):2461.

PMID: 38291045 PMC: 10827780. DOI: 10.1038/s41598-024-51292-4.

Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.

Evon D, Lin H, Khalili M, Wahed A, Yim C, Fontana R Dig Dis Sci. 2023; 68(12):4499-4510.

PMID: 37804353 PMC: 11149619. DOI: 10.1007/s10620-023-08108-8.

Saussakova S, Dauletova G, Nakipov Z, Sarsenbayeva G, Duisekova S, Sadibekova Z Iran J Public Health. 2023; 52(3):453-462.

PMID: 37124905 PMC: 10135505. DOI: 10.18502/ijph.v52i3.12129.

References

Angevine P, Berven S . Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses. Spine (Phila Pa 1976). 2014; 39(22 Suppl 1):S9-15. DOI: 10.1097/BRS.0000000000000576. View

Younossi Z, Stepanova M, Younossi I, Papatheodoridis G, Janssen H, Agarwal K . Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int. 2019; 39(10):1837-1844. DOI: 10.1111/liv.14171. View

Gao R, Gao F, Li G, Hao J . Health-related quality of life in chinese patients with chronic liver disease. Gastroenterol Res Pract. 2012; 2012:516140. PMC: 3371692. DOI: 10.1155/2012/516140. View

Evon D, Lin H, Khalili M, Fontana R, Yim C, Wahed A . Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther. 2020; 51(4):457-468. PMC: 6989387. DOI: 10.1111/apt.15618. View

Kim S, An J, Lim Y, Han S, Lee J, Byun J . MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2016; 3(4):456-463. PMC: 5470420. DOI: 10.1001/jamaoncol.2016.3147. View

Sarin S, Kumar M, Eslam M, George J, Al Mahtab M, Akbar S . Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019; 5(2):167-228. PMC: 7164809. DOI: 10.1016/S2468-1253(19)30342-5. View

Wang K, Li M, Qin J, Sun G, Dai L, Wang P . Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes. Cancers (Basel). 2020; 12(5). PMC: 7280966. DOI: 10.3390/cancers12051271. View

Qiao C, Zhai X, Ling C, Lang Q, Dong H, Liu Q . Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol. 2012; 18(21):2689-94. PMC: 3370007. DOI: 10.3748/wjg.v18.i21.2689. View

Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K . Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014; 12:101. PMC: 4067057. DOI: 10.1186/1477-7525-12-101. View

10.

. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2008; 50(2):227-42. DOI: 10.1016/j.jhep.2008.10.001. View

11.

Brazier J, Roberts J, Deverill M . The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002; 21(2):271-92. DOI: 10.1016/s0167-6296(01)00130-8. View

12.

Higgins A, Harris A . Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. Crit Care Clin. 2011; 28(1):11-24, v. DOI: 10.1016/j.ccc.2011.10.002. View

13.

Bruix J, Sherman M . Management of hepatocellular carcinoma. Hepatology. 2005; 42(5):1208-36. DOI: 10.1002/hep.20933. View

14.

Lam E, Lam C, Lai C, Yuen M, Fong D, So T . Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes. 2009; 7:52. PMC: 2701941. DOI: 10.1186/1477-7525-7-52. View

15.

Cui F, Shen L, Li L, Wang H, Wang F, Bi S . Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017; 23(5):765-772. PMC: 5403029. DOI: 10.3201/eid2305.161477. View

16.

Schackman B, Gold H, Stone P, Neumann P . How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?. Pharmacoeconomics. 2004; 22(5):293-300. DOI: 10.2165/00019053-200422050-00003. View

17.

Henrique Lima P, Fan B, Berube J, Cerny M, Olivie D, Giard J . Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol. 2019; 213(1):17-25. DOI: 10.2214/AJR.18.20341. View

18.

Cella D, Stone A . Health-related quality of life measurement in oncology: advances and opportunities. Am Psychol. 2015; 70(2):175-85. DOI: 10.1037/a0037821. View

19.

Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q . Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19(1):811. PMC: 6751646. DOI: 10.1186/s12879-019-4428-y. View

20.

Lam C, Brazier J, McGhee S . Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population. Value Health. 2008; 11(2):295-303. DOI: 10.1111/j.1524-4733.2007.00233.x. View